-

Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a conference call to review the company's fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (800) 446-1671 (US/Canada) or (847) 413-3362 (International) and use the confirmation number "50233346" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

DexCom, Inc.:

Investors
Sean Christensen
Senior Director, Investor Relations and Corporate FP&A
(858) 203-6657
www.dexcom.com

Media
James McIntosh
(619) 884-2118

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time
Release Versions
English
$Cashtags
$DXCM
Hashtags
#DXCM

Contacts

DexCom, Inc.:

Investors
Sean Christensen
Senior Director, Investor Relations and Corporate FP&A
(858) 203-6657
www.dexcom.com

Media
James McIntosh
(619) 884-2118

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom